Cancer Supportive Care is emerging as a significant growth area for the biotechnology and pharmaceutical industry. With the dramatic improvement in the survivorship of cancer patients, focus is rapidly shifting to the development of new drugs and therapeutics that address the complications of cancer treatment.
Biomodels has become a leader in Cancer Supportive Care through its expertise in developing innovative models based on an understanding of the toxicity associated with chemotherapy and radiotherapy in the treatment of carcinomas.
Biomodels is internationally recognized for its groundbreaking work in oral mucositis. We have also developed innovative models in drug development for procitis, osteoncrosis, fatigue, dermatisis, hemostatis, myelosuppression, and neurological toxicity.